References
Mizrahi JD, Surana R, Valle JW, Shrof RT (2020) Pancreatic cancer. Lancet 395(10242):2008–2020. https://doi.org/10.1016/S0140-6736(20)30974-0
Gillen S, Schuster T, Büschenfelde CM Zum et al (2010) Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 7. https://doi.org/10.1371/JOURNAL.PMED.1000267
Porrello G (2023) Can a CT-based nomogram predict recurrence in resectable pancreatic body and tail adenocarcinoma? Eur Radiol 33(11):7779–7781. https://doi.org/10.1007/s00330-023-10193-2
Zins M, Matos C, Cassinotto C (2018) Pancreatic adenocarcinoma staging in the era of preoperative chemotherapy and radiation therapy. Radiology 287(2):374–390. https://doi.org/10.1148/radiol.2018171670
Barral M, Taouli B, Guiu B et al (2015) Diffusion-weighted MR imaging of the pancreas: current status and recommendations. Radiology 274:45–63. https://doi.org/10.1148/radiol.14130778
Morone M, Bali MA, Tunariu N et al (2017) Whole-body MRI: current applications in oncology. AJR Am J Roentgenol 209:W336–W349. https://doi.org/10.2214/AJR.17.17984
Bilreiro C, Andrade L, Marques RM, Matos C (2023) Diffusion-weighted imaging for determining response to neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis. Eur Radiol 1. https://doi.org/10.1007/s00330-023-10381-0.
Funding
The author states that this work has not received any funding.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Guarantor
The scientific guarantor of this publication is Vincent Vandecaveye.
Conflict of interest
The author of this manuscript declares no relationships with any companies, whose products or services may be related to the subject matter of the article.
Statistics and biometry
No complex statistical methods were necessary for this paper.
Informed consent
Written informed consent was not required for this study because this is a commentary.
Ethical approval
Institutional Review Board approval was not required because this is a commentary.
Study subjects or cohorts overlap
Not applicable.
Methodology
• commentary
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This comment refers to the article available at https://doi.org/10.1007/s00330-023-10381-0.
Rights and permissions
About this article
Cite this article
Vandecaveye, V. Can diffusion-weighted MRI improve response assessment of neo-adjuvant therapy in pancreatic cancer?. Eur Radiol (2023). https://doi.org/10.1007/s00330-023-10528-z
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1007/s00330-023-10528-z